Thomas Marsland, MD, medical oncologist, discusses his take on the CAR T-cell therapy reimbursement plan put forward by CMS.
Thomas Marsland, MD, medical oncologist, discusses his take on the CAR T-cell therapy reimbursement plan put forward by CMS.
Transcript:
What are your thoughts about the [chimeric antigen receptor] CAR T-cell therapy reimbursement plan introduced by CMS? Will it help or hurt patient access to these life-saving therapies?
Just to make a couple generic comments, there’s an old saying that ‘be careful what you ask for.’ I was the care advisory committee representative for years and looked at local coverage determinations. So, I think, we take that with a little bit of salt— local coverage determinations and for that matter national coverage determinations– sort of set the ground rules as to exactly what it is. And you know, it also limits in many ways. I think the concerns are that this national coverage determination for CAR T cells may, in some ways at least, be too narrow or too restrictive in the sense that it limits it to just certain institutions. As I said, I don’t ever see CAR T cells as being something that every medical oncologist is going to be doing. There are certainly big practices in private communities and private practices that potentially have the capabilities of doing that.
One of the other concerns with that national coverage determination was that it limited off-label coverage just to one of the compendia whereas historically we’ve always used off-label coverages for several compendia that we’ve been allowed to use. So, I think that’s a bit of a concern.
The coverage with evidence-based determination is, I think, a good thing. I lived through that with [positron emission tomography] PET scanning and prostate cancer and I think that was a wise thing that CMS did to do that, and they came out with policy after that that I think was appropriate.
The concern there though is that the reporting burden for this may be a little bit too great for some of the things and they’re maybe asking and expecting too much to be reported. It’s that administrative work that then becomes prohibitive sometimes. I mean, there’s already a lot of administrative burdens that we’re facing, and any more paperwork would not be a good thing.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More